CYC-116, identified by its CAS number 693228-63-6, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is classified as a small molecule and is known to act as a selective inhibitor of certain kinases, which are enzymes that play crucial roles in various cellular processes, including cell growth and division. The compound's structure typically features specific functional groups that contribute to its biological activity and selectivity. CYC-116 has been studied for its efficacy in treating various types of cancer, as it may interfere with the signaling pathways that promote tumor growth. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are essential for determining its suitability for clinical use. Ongoing research aims to further elucidate its mechanism of action, optimize its therapeutic profile, and assess its safety and effectiveness in clinical settings.

CYC-116

693228-63-6: CYC-116, identified by its CAS number 693228-63-6, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is classified as a small molecule and is known to act as a selective inhibitor of certain kinases, which are enzymes that play crucial roles in various cellular processes, including cell growth and division. The compound's structure typically features specific functional groups that contribute to its biological activity and selectivity. CYC-116 has been studied for its efficacy in treating various types of cancer, as it may interfere with the signaling pathways that promote tumor growth. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are essential for determining its suitability for clinical use. Ongoing research aims to further elucidate its mechanism of action, optimize its therapeutic profile, and assess its safety and effectiveness in clinical settings.

2-Pyrimidinamine,4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-

CYC116

CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active

CAS 693228-63-6

CYC-116

2-Pyrimidinamine,4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-

Ref: IN-DA00FAG5

CYC-116

Ref: 54-BUP10080

CYC116

Ref: 7W-GW0803

CYC-116

Ref: TM-T6458